Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03137121|
Recruitment Status : Completed
First Posted : May 2, 2017
Results First Posted : August 17, 2021
Last Update Posted : August 17, 2021
|Condition or disease||Intervention/treatment||Phase|
|Advanced Cancer||Drug: Olanzapine Other: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||There will be two groups for the study: Olanzapine Group will receive the study drug and Placebo Group will receive a placebo.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||Patients will receive the study drug or placebo in a double-blind fashion.|
|Official Title:||Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patient - A Pilot, Dose-Finding Trial|
|Actual Study Start Date :||July 12, 2017|
|Actual Primary Completion Date :||July 12, 2019|
|Actual Study Completion Date :||September 15, 2020|
Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
Olanzapine is used as an anti-emetic.
Other Name: Zyprexa
Placebo Comparator: Placebo
Patients will receive a placebo orally for 1 to 7 days daily.
The placebo is a non-anti-emetic.
- Mean Nausea Scores [ Time Frame: Nausea score from the Visual Analogue Scale will be recorded each day daily for 7 days. An average value calculated will be reported for the 7 day period. ]
Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured.
Patients will be asked to record the average nausea score for each day in a diary and a study nurse will call the patient at the same time each day to remind the patient to record the nausea score and to inquire about any toxicities. The difference in the nausea scores for the patients in each group (Olanzapine and Placebo) will be compared.
- Number of Emetic Episodes [ Time Frame: Number of emetic episodes for each patient on each day of the seven day treatment. ]The number of emetic episodes (a secondary outcome) by each patient in each group, Olanzapine & Placebo, on each day of treatment will be recorded by each patient on each day of treatment in a diary. A study nurse will contact each patient at the same time of each day of the study to ask the patient to record the number of emetic episodes and report any toxicities.The number of emetic episodes for the patients in each Group for each day of the treatment will be compared.
- Number of Treatment-related Adverse Events as Assessed by CTCAE v4.0". [ Time Frame: Daily assessment for 7 days for each patient in Olanzapine & Placebo Groups. ]Adverse events will be measured by patient-reported outcomes questionnaires and the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A study nurse will contact each patient each day of the seven days of treatment to inquire about any toxicities, specifically sedation and appetite. Sedation and appetite will be reported by the patient in each Group on a Visual Analogue Scale of 0 to 10 with 0 being no sedation or no appetite to 10 indicating maximum sedation or maximum appetite.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03137121
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, Indiana|
|Indianapolis, Indiana, United States, 46202|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|
|United States, Wisconsin|
|Hospital Sisters Health System (HSHS) St. Vincent Hospital|
|Green Bay, Wisconsin, United States, 54301|
|Principal Investigator:||Rudolph Navari, MD||University of Alabama at Birmingham|